|
|
Article: NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors.
- Article from:
- Obesity & Diabetes Week
- Article date:
- November 2, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NGM Biopharmaceuticals, Inc. (NGM), a private company dedicated to the discovery and development of novel biotherapeutics for the treatment of Type 2 diabetes and other metabolic diseases, announced that Arthur D. Levinson, Ph.D., the Chairman of Genentech's Board of Directors, has been appointed to NGM's Board of Directors. Under Dr. Levinson's leadership as Chairman and Chief Executive Officer from 1995 to 2009, Genentech became a leading global therapeutics company that was widely recognized as the most innovative biotechnology company in the industry (see also Type 2 Diabetes).
Founded in 2008, NGM has created a proprietary discovery platform and pipeline ...